Myocardial ischemia correlates with reduced fibrinolytic activity following peripheral vascular surgery

J Clin Anesth. 2000 Mar;12(2):136-41. doi: 10.1016/s0952-8180(00)00126-4.

Abstract

Study objectives: To evaluate the relationship between perioperative ischemia and serial concentrations of D-dimer, which is a sensitive and specific marker of fibrinolytic activity. Myocardial ischemia and infarction are well-recognized complications of peripheral vascular surgery. We hypothesized that patients at increased risk of perioperative myocardial ischemia might be identified preoperatively by abnormal hemostatic indices.

Design: Prospective clinical outcomes study.

Setting: A 1,124-bed tertiary care medical center.

Patients: 42 ASA physical status II, III, and IV patients undergoing peripheral vascular surgery.

Interventions: Serial D-dimer concentrations were measured preoperatively, and at 24 and 72 hours postoperatively. Continuous 12-lead ST-segment monitoring (Mortara Instrument, Inc., Milwaukee, WI) was performed with the acquisition of a 12-lead ECG every 20 seconds for 72 hours.

Measurements and main results: D-dimer measurements were performed in duplicate using the Dimer Gold assay (American Diagnostica, Greenwich CT). Ischemic episodes, as defined by continuous 12-lead ST-segment monitoring, occurred in 49% of patients. There were no demographic differences between ischemic and nonischemic groups. Although baseline D-dimer concentrations were not statistically significantly different between groups, patients experiencing perioperative myocardial ischemia generated significantly less D-dimer during the perioperative period (p = 0. 014).

Conclusions: PATIENTS with an impaired fibrinolytic response, as defined by reduced generation of D-dimer, experienced an increased incidence of perioperative myocardial ischemia.

MeSH terms

  • Aged
  • Antifibrinolytic Agents / blood*
  • Biomarkers / blood
  • Chi-Square Distribution
  • Electrocardiography, Ambulatory
  • Female
  • Fibrin Fibrinogen Degradation Products / analysis*
  • Fibrinolysis / drug effects*
  • Follow-Up Studies
  • Humans
  • Incidence
  • Intraoperative Complications
  • Male
  • Middle Aged
  • Myocardial Ischemia / etiology*
  • Outcome Assessment, Health Care
  • Prospective Studies
  • Risk Factors
  • Vascular Surgical Procedures / adverse effects*

Substances

  • Antifibrinolytic Agents
  • Biomarkers
  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D